US HB8190 | 2019-2020 | 116th Congress
Status
Spectrum: Bipartisan Bill
Status: Introduced on September 8 2020 - 25% progression, died in chamber
Action: 2020-09-16 - Sponsor introductory remarks on measure. (CR H4487)
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on September 8 2020 - 25% progression, died in chamber
Action: 2020-09-16 - Sponsor introductory remarks on measure. (CR H4487)
Text: Latest bill text (Introduced) [PDF]
Summary
To amend the Public Health Service Act to deem any insulin that is determined by the Secretary to be biosimilar to the reference product to be interchangeable with the reference product, and for other purposes.
Title
Biosimilar Insulin Access Act of 2020
Sponsors
| Rep. Glenn Grothman [R-WI] | Rep. Michael San Nicolas [D-GU] |
History
| Date | Chamber | Action |
|---|---|---|
| 2020-09-16 | House | Sponsor introductory remarks on measure. (CR H4487) |
| 2020-09-08 | House | Referred to the House Committee on Energy and Commerce. |
| 2020-09-08 | House | Introduced in House |
Subjects
Blood and blood diseases
Competition and antitrust
Drug safety, medical device, and laboratory regulation
Drug therapy
Health
Health technology, devices, supplies
Intellectual property
Licensing and registrations
Prescription drugs
Competition and antitrust
Drug safety, medical device, and laboratory regulation
Drug therapy
Health
Health technology, devices, supplies
Intellectual property
Licensing and registrations
Prescription drugs
US Congress State Sources
| Type | Source |
|---|---|
| Summary | https://www.congress.gov/bill/116th-congress/house-bill/8190/all-info |
| Text | https://www.congress.gov/116/bills/hr8190/BILLS-116hr8190ih.pdf |
